ArticleNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2023
Interactions Between Antidepressants and Intestinal Microbiota.
Article in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Neurobiological effects of microbial treatments within psychiatry: a systematic review.Frontiers in psychiatry · 2026Pooled it
- Role of Probiotics in Management of Depressive Symptoms and Cognitive Impairment in Patients With Depression: An Updated Analysis of Trials.Brain and behavior · 2025Pooled it
- Psychopharmacological Therapy Positively Modulates Disease Activity in Inflammatory Bowel Disease: A Systematic Review.International journal of molecular sciences · 2025Pooled it
- Metabolic Status Influences Probiotic Efficacy for Depression-PRO-DEMET Randomized Clinical Trial Results.Nutrients · 2024Trial
- Giardiasis and Bupropion-Associated Gastrointestinal Symptoms in a Returning Traveler: A Diagnostic Challenge Case Report.Reports (MDPI) · 2026Article
- Fluoxetine-Induced Changes in Escherichia coli Physiology: Effects of Secreted Metabolites on Cell Viability and Colistin Susceptibility.Probiotics and antimicrobial proteins · 2026Article
- GV-971 Ameliorates Chronic Restraint Stress-Induced Depression-like Phenotypes Accompanied by Reshaping of the Microbiota-Gut-Brain Axis.Marine drugs · 2026Article
- The gut microbiome shapes social behaviour across animal species.Nature reviews. Microbiology · 2026Review
- Mapping the reciprocal interactions between antidepressants and the gut microbiome: novel targets for the personalisation and optimization of drug response.Molecular psychiatry · 2026Review
- Article
- Oral dryness related symptoms in radiation-treated head and neck cancer patients: a pilot study of oral microbiome composition and function.BMC microbiology · 2026Article
- Tracking Metabolic Responses to Citalopram in Colon Cells with Raman Spectroscopy.Analytical chemistry · 2026Article
- Plant-derived bioactives, the gut-brain axis, and neurodegenerative diseases: mechanistic roles of diet-microbiota interactions.Frontiers in neuroscience · 2026Review
- Pharmacological interventions targeting the gut-brain axis in neurological disorders: mechanisms and translational applications.Frontiers in neuroscience · 2026Review
- Article
- Microbiome driven modulation of neurotransmitters: implications for neurotransmission and mood disorders.Frontiers in microbiology · 2026Review
- Gut microbiota, circadian rhythms and their interactions: implications for the pathogenesis and treatment of depression.Annals of medicine · 2025Review
- Relief from Chronic Unpredictable Mild Stress-Induced Constipation by Fluoxetine and Butyrate and Their Impact on Gut Microecology.Drug design, development and therapy · 2025Article
- Does isovaleric acid play a key role in the interaction between probiotics and antidepressants? A secondary analysis of a randomized clinical trial.Computational and structural biotechnology journal · 2025Article
- Microbiome: A Key Regulator of Body-Brain Interactions.Advances in experimental medicine and biology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The microbiota-gut-brain axis has been shown to influence human health and diseases, including depression. The interactions between drugs and intestinal microbiota are complex and highly relevant to treat diseases. Studies have shown an interaction between antidepressants and intestinal microbiota. Antidepressants may alter the abundance and composition of intestinal microbiota, which are closely related to the treatment outcomes of depression. Intestinal microbiota can influence the metabolism of antidepressants to change their availability (e.g., tryptophan can be metabolized to kynurenine by intestinal microbiota) and regulate their absorption by affecting intestinal permeability. In addition, the permeability of the blood-brain barrier can be altered by intestinal microbiota, influencing antidepressants to reach the central nervous system. Bioaccumulation is also a type of drug-microbiota interaction, which means bacteria accumulate drugs without biotransformation. These findings imply that it is important to consider intestinal microbiota when evaluating antidepressant therapy regimens and that intestinal microbiota can be a potential target for depression treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.